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Patients and methods: Between 1971 and 1993, 656 conduits were placed in the
subpulmonary position. Patients receiving heterografts or valveless conduits
and patients dying within 90 days of insertion were excluded; thus 405
homograft conduits were studied. There were 293 aortic homografts, 94
pulmonary, and 18 of unknown type. The end point of conduit failure was
defined by conduit replacement for whatever reason, balloon dilation of the
conduit, or death of the patient with the conduit in place. The following factors
were analyzed: aortic versus pulmonary homograft, antibiotic preservation
versus cryopreservation, ABO and Rh compatibility, type of material used for
conduit extension, age at operation, size of the conduit, diagnosis, and
reoperations. Conduit number (1 to 405) in the series was included in the
multivariable model. Results: First conduits and conduits inserted earlier in the
series appeared to last longer than second and subsequent conduits and those
inserted later in the series (p 5 0.001 and 0.003, respectively). Overall survival
of conduits at 5, 10, and 15 years was 84% (95% CL, 80% to 88%), 58% (95%
CL, 50% to 66%), and 31% (95% CL, 19% to 43%). Corresponding figures for
the first conduits were 88% (95% CL, 84% to 92%), 65% (95% CL, 56% to 73%),
and 34% (95% CL, 20% to 47%). The longest surviving homograft conduit in
our series lasted 22.7 years. Regarded univariately, reoperation (redo worse),
order number (recent worse), type of conduit (pulmonary worse than aortic),
preservation (cryopreserved worse than antibiotic preserved), and age at
operation (older patients worse) were statistically significant. However, in
multivariable analysis, including all the above in the model, only reoperation
and order number had significant predictive power. When patient survival was
considered, patients operated on more recently survived longer despite the fact
that their conduits were being replaced earlier. Overall, survival of patients at
5 and 15 years was 95% (95% CL, 93% to 98%) and 85% (95% CL, 77% to 92%),
respectively. Conclusions: Pulmonary and aortic homografts, both cryopre-
served and preserved in nutrient antibiotic solution, give similar results. All
conduits will probably have to be replaced during the lifetime of the patient. In
view of the worse performance of replacement conduits, techniques of repair
that avoid the use of conduits should be further explored. Despite gradual
deterioration of homograft conduits, they remain an important tool in the
correction of many complex lesions with excellent 15-year patient survival.
(J Thorac Cardiovasc Surg 1998;115:506-16)
Extracardiac valved conduits between the subpul-monary ventricle and the pulmonary artery have
been used in the repair of many complex congenital
heart defects since 1966.1-3 After the pioneering
work of Ross and Somerville1 with antibiotic-pre-
served homografts, preservation with irradiation was
widely used in the United States. This was associ-
ated with early calcification and stenosis and wide-
spread abandonment of homografts. Dacron con-
duits containing porcine heterografts4 became
available commercially in various sizes and for many
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became the conduit of choice. However, formation
of neointimal peel inside Dacron conduits,5 as well
as early degeneration of porcine valves in children,
caused further disappointment. Preparation of ho-
mografts with cryopreservation6 and, more recently,
the introduction of pulmonary homografts have
provoked resurgence of their use.
This article is a retrospective analysis of the
long-term results of a large series of homograft
conduits inserted in the subpulmonary position, with
particular emphasis on the determinants of their
longevity.
Patients and methods
Between 1971 and 1993, 656 conduits were placed
between the subpulmonary ventricle and the pulmonary
artery (Fig. 1). Patients receiving heterografts or valveless
conduits and those dying within 90 days of the operation
were excluded from this study. Thus 405 homograft con-
duits were evaluated: 293 aortic, 94 pulmonary, and 18 of
unknown type. The most common diagnostic groups are
shown on Table I. There were 73 conduit replacements.
Surgical technique of homograft insertion has changed
over the years. At the beginning, large homografts were
used, even in infants. Smaller conduits were used during
recent years to decrease the dead space. In older children
we always tried to accommodate a homograft that was
larger than the expected size of the pulmonary valve ring
for the child’s age and body surface area. The anterior
cusp of the mitral valve of the homograft was used for
right ventricular outflow tract reconstruction. In later
years a patch (pericardium, Dacron, polytetrafluoroethyl-
ene,* or homograft) was used to reconstruct the outflow
from the right ventricle. Any stenoses at the bifurcation or
at the site of a ductus or a shunt were repaired at the time
of conduit insertion.
Homografts were obtained either at routine autopsies
in clean but nonsterile conditions or from multiorgan
donors under operating theater conditions. Most were
processed at the laboratories of the National Heart Hos-
pital. At the beginning of the series, homografts were
preserved in nutrient antibiotic solution and stored at
4° C. The composition of the antibiotic solution changed
over the years. Cryopreserved homografts7 became avail-
able in 1989 and both techniques of homograft preserva-
tion have been used since. Preference was given to
homografts from younger donors and homograft stored
for less than 3 weeks.8 No attempt at ABO or Rh
matching was made. Pulmonary homografts became avail-
able in the late 1980s. The choice between aortic and
pulmonary homografts was based on availability and the
surgeon’s preference and was not protocol driven or
randomized.
Although we have objective information about how
some aspects of management changed over the years
(such as homograft type, preservation, prevalence of
reoperations, and age at operation), other aspects such as
indications for conduit replacement are more subtle.
Recognizing that these more subtle trends in practice
might also influence conduit survival in our patients, we
*Gore-Tex graft, registered trade mark of W. L. Gore & Asso-
ciates, Inc., Elkton, Md.
Fig. 1. Homograft and heterograft conduits used in the repair of complex congenital heart defects
between 1971 to 1993 in our department.
Table I. Diagnoses of patients who received
homograft conduits in the subpulmonary position
(Great Ormond Street Hospital, 1971 to 1993)
No.
TGA 1 VSD 1 LVOTO 108
Pulmonary atresia 1 VSD 90
Truncus arteriosus 78
Fallot’s tetralogy 53
Atrioventricular discordance 31
Absent pulmonary valve 1 VSD 16
Other 29
Total 405
TGA, Transposition of the great arteries; VSD, ventricular septal defect;
LVOTO, left ventricular outflow tract reconstruction.
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have used the concept of “order number” in our analysis.9
The first conduit in 1971 was allocated number 1 and the
last in the series was number 405.
Follow-up was in the first quarter of 1994, with infor-
mation from our own pediatric cardiology clinics or from
the referring physicians being used. In cases in which
follow-up was incomplete, no assumptions were made
about the patients’ status beyond their last contact with
our hospital. The following data were collected for anal-
ysis: diagnosis, age at operation and at last visit, reinter-
vention or death, conduit type (aortic or pulmonary), size,
mode of preservation (antibiotic preservation or cryo-
preservation), ABO and Rh compatibility between donor
and recipient, and the material used for conduit extension
(pericardium, polytetrafluoroethylene, Dacron, or “oth-
er”). In cases in which a conduit was replaced, the number
of conduits (including heterografts and valveless tubes)
previously used in that patient were noted. Retrospec-
tively, it was not possible to identify the exact mechanism
of conduit failure. Thus conduit replacement for conduit
valve stenosis, stenosis at a proximal or distal anastomosis,
stenosis of the conduit itself, endocarditis, aneurysm or
pseudoaneurysm of the conduit, and compression of the
conduit by sternum were all included as conduit failures.
Statistical methods. The end points for analyses of
conduit survival were conduit replacement for any reason,
reintervention on that conduit, or death of the patient
with that conduit in place. Survival curves for the ho-
mograft conduits and for subsets of the whole group (e.g.,
contrasting aortic and pulmonary homografts) and for
patient survival were prepared by means of Kaplan-Meier
methods.10 Survival figures are quoted with 95% confi-
dence limits (CL). Univariable and multivariable analysis
of risk factors for conduit survival was performed by
means of a Cox proportional hazards method11 and the
same outcome end points; factors entering the final model
were chosen by means of statistical and clinical criteria.
Results
Conduit survival. Follow-up ranged from 3
months to 22.8 years (mean 5.4 years). Mean age at
operation was 6.8 years (range 2 days to 28 years).
Of the group, 15% were infants and 15% were older
than 12.5 years. The earliest conduit replacement
was at 9 months, and our longest lasting conduit has
been in place for 22.8 years. There were 60 first
reoperations, 11 second, 1 third, and 1 fourth-time
conduit replacement, 13 balloon dilatations, and 15
late deaths unassociated with reoperation with the
conduit in place. Actuarial survival of all homograft
conduits is shown in Fig. 2. Freedom from conduit
replacement at 5, 10, and 15 years was 84% (95%
CL, 80% to 88%), 58% (95% CL, 50% to 66%), and
31% (95% CL, 19% to 43%), respectively.
Univariable analysis. Looked at first in isolation,
the factors that were considered possibly relevant to
longevity are listed in Table II. These were conduit
replacement (favoring first operations over reopera-
tions, Fig. 3), order number (favoring conduits
earlier in the series), age at operation (favoring
young age at operation, Fig. 4), aortic versus pulmo-
nary (favoring aortic, Fig. 5), and preservation tech-
nique (favoring antibiotic preservation over cryo-
preservation, Fig. 6). There was little separation of
longevity according to the diagnosis or choice of
conduit extension. Conduit size (Fig. 7), ABO com-
patibility (Fig. 8), and Rh compatibility seemed
irrelevant to conduit longevity.
Multivariable analysis. The two most powerful
predictors of conduit survival related to the ob-
served decrease in longevity of second compared
with first conduits and to recent order number. The
latter effect was not accounted for by the increasing
prevalence of reoperations over time. When reop-
erations and order number were taken into account
in a multivariable analysis, the apparent disadvan-
Fig. 2. Survival of homograft conduits at 5, 10, and 15 years. Numbers on this and subsequent figures show
number of patients at risk.
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tage of older age at operation, pulmonary over
aortic homografts, and cryopreservation over anti-
biotic preservation lost significance. All these factors
were confounded with recent order number.
In the final model (Table II), which attempts to
evaluate independently each possible risk factor,
only two remain significant: order number and re-
operation (use of second and subsequent conduit).
Patient survival. Overall subsequent survival, re-
gardless of intervening reoperations, of all 405 pa-
tients receiving homograft conduits in the era 1971
to 1993 who survived at least 90 days from their first
conduit insertion is shown in Fig. 9. Patients receiv-
ing their first conduit before and after 1980 are
contrasted. When an “order number” was applied to
this data set according to the date of the patient’s
first operation, recent order number was associated
with increased patient survival (p 5 0.0009).
Discussion
The aim of this study was to investigate the
determinants of longevity of homograft conduits. In
particular, we wanted to know if there were factors
intrinsic to the conduit itself that would influence
how long it would last in a patient. These factors
included type of homograft (aortic versus pulmo-
nary), mode of preservation (antibiotic versus cryo-
preservation), ABO and Rh compatibility with the
recipient, and conduit size. To investigate these
possibilities in an observational study, we also had to
understand the influence of a variety of other factors
extrinsic to the conduit itself; these include the
underlying diagnosis of the patients and whether the
conduit was the first, second, third, or fourth conduit
for that patient. Over the years practice regarding
conduit management has changed in many respects;
in cases in which we have objective data about how
Fig. 3. Survival of first conduits compared with survival of replacement conduits.
Table II. Univariate and multivariable analysis of risk factors for conduit failure
Univariate Multivariate
Factor Worse B p Factor Worse B p
First conduit or redo Redo 1.08 0.00001 First conduit or redo Redo 1.06 0.00001
Order number Recent 0.0065 0.00001 Order number Redo 0.005 0.003
Age at operation (yr) Older 0.65 0.002 Age at operation 0.01 0.64
Aortic or pulmonary Pulmonary 0.46 0.04 Aortic or pulmonary 0.57 0.06
Preservation Cryopreservation 0.05 0.05 Preservation 20.19 0.55
Conduit size (mm) 0.03 0.35 Conduit size (mm) 0.002 0.97
ABO match 0.21 0.45
Rh match 20.05 0.90
Conduit extension
(pericardium vs “else”)
20.13 0.08
Diagnosis (truncus vs
“else”)
20.31 0.24
B, Regression coefficient (the log of the odds on death for a given patient compared with the baseline).
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these changed over time, we can allow for their
interaction in the analysis. Others changes in “fash-
ions” about conduit management (such as indica-
tions for elective conduit replacement) are much
less easy to handle rigorously because the changes in
practice have been gradual and not protocol driven.
No mechanism exists for directly measuring con-
duit deterioration; conduit survival in the patient
was used as a proxy measurement. Unfortunately,
conduit survival in a patient is determined by factors
other than deterioration of the conduit. Conduit
replacement, for whatever reason, other interven-
tion on the conduit (e.g., a balloon dilatation), or the
death of the patient with that conduit in place was
considered as conduit failure. These together will
probably overestimate the prevalence of conduit
deterioration, but there is no reason to expect that
choice of these end points will produce a spurious
bias in the analysis of possible risk factors. Also,
because our main interest was in the determinants
of the conduit deterioration beyond the immediate
postoperative period, only data from conduits still in
place 90 days after insertion were included; conduit
deterioration rarely accounts for early postoperative
death or need for conduit revision. Most other
articles include the early postoperative hazard,
which almost certainly has different determinants.
Replaced conduits. Our finding that the second
and subsequent conduits had shorter freedom from
failure (see Fig. 3) than the original conduits was
surprising and rather worrisome. We suspect that
technical details may play an important role. Be-
Fig. 4. Survival of homograft conduits in three age groups (,1, 1-3, and .3 years).
Fig. 5. Survival of aortic homografts compared with survival of pulmonary homografts.
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cause of adhesions and calcification of adjacent
tissues, it may be more difficult to obtain an ideal fit
and flow characteristics at reoperation. In addition,
there may be a variety of other subtle technical
details that have yet to be identified. Another argu-
ment supporting the importance of operative tech-
nique is information published by Razzouk and
associates12 from Toronto. In their series, the best
results were achieved with pulmonary valve inser-
tion rather than with use of the conduit. Five-year
survival after pulmonary valve insertion was 89% 6
5% irrespective of whether a homograft or hetero-
graft valve was used. This contrasted with 5-year
survival of 46% 6 1.3% of homograft conduits.
Because of these findings about replacement con-
duits, we believe that techniques of repair avoiding
conduits13-15 should be further explored.
Order number. The second factor relevant to
conduit longevity in our series was the “order num-
ber.” Surprisingly, it was not the recent but the early
conduits that lasted longer. This was not accounted
for by the increasing prevalence of reoperation with
time. Looking at the long-term survival of patients
as opposed to survival of the conduits, the patients’
survival in recent years was better than in earlier
years. For this not to be a paradox, we suggest that
the explanation lies in our increasing readiness to
reoperate early on inadequate conduits. Experience
Fig. 6. Survival of homografts preserved in nutrient/antibiotic solution compared with survival of
cryopreserved homografts.
Fig. 7. Survival of small (,15 mm) and large (.15 mm) homograft conduits.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Stark et al. 5 1 1
of others16, 17 and our own increasing experience
confirmed that conduits can be replaced with low
risk and that the function of the ventricle may
determine the patient’s outcome after conduit re-
placement. As a consequence, conduit replacement
is now probably undertaken earlier than in the past.
Thus, in our analysis, shorter survival of the conduits
in recent years may be appropriate as the pattern is
associated with improved survival of the patients
over time.
Aortic versus pulmonary conduits. When pulmo-
nary homografts were introduced as right ventricu-
lar outflow tract conduits, it was hoped that they
would perform better than the aortic homografts.
Freedom from reoperation was better in pulmonary
compared with aortic homografts in some series.18-20
Schorn and coworkers20 found freedom from calci-
fication to be 100% at 1 year for pulmonary ho-
mografts and 33% for aortic homografts. Five-, 10-,
and 15-year survival of aortic homografts in our
series was 87% (95% CL, 83% to 91%), 60% (95%
CL, 52% to 69%), and 34% (95% CL, 19% to 48%)
compared with 73% (95% CL, 62% to 85%), 55%
(95% CL, 36% to 74%), and 24% (95% CL, 3% to
46%) for pulmonary homografts (see Fig. 5). In
multivariable analysis this difference was not strictly
significant (p 5 0.06); in our series, use of pulmo-
nary homografts was confounded with “recent order
number” and with reoperation. Freedom from re-
operation was similar for aortic and pulmonary
homografts in the experience of Cleveland,21
Hawkins,22 and their colleagues.
Fig. 8. Survival of ABO matched and mismatched homografts.
Fig. 9. Long-term survival of patients (who survived 90 days after conduit insertion).
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Methods of preservation. Cryopreservation im-
proved longevity of aortic homograft valves placed
in the aortic position.6, 23 Cryopreservation of ho-
mograft conduits did not produce similar results.
Cleveland and coworkers,21 reporting results from
Toronto, concluded that performance of cryopre-
served homografts in the pulmonary position was
disappointing. Homografts preserved in antibiotic/
nutrient solution performed well in the experience
of Kay and Ross24 and Tam and colleagues.25 In our
series, cryopreserved homografts appeared to per-
form somewhat worse (see Fig. 6), but the difference
could be accounted for by association with recent
patient number and—according to our hypothesis—
with earlier reintervention on deteriorating ho-
mografts in recent years. Thus we believe that the
use of both types of preservation is justified. Cryo-
preservation has the additional advantage of longer
storage time compared with antibiotic/nutrient so-
lutions.
Age factor for conduit failure. Contrary to results
of other studies,12, 18, 20, 24, 26 young age was not a
significant risk factor for conduit survival in our
series. Five-year freedom from reoperation was 43%
in Clarke and Bishop’s series27 and 48% in Schorn’s
data.20 Age under 4 years was a risk factor in the
Mayo Clinic experience.18 These data contrast with
our 5- and 10-year freedom from conduit failure for
the conduits that were still in place 90 days after the
original operation. It was 91% (95% CL, 82% to
98%) and 77% (95% CL, 58% to 96%) for infants
(see Fig. 4), 81% (95% CL, 67% to 95%) and 46%
(95% CL, 23% to 69%) for 1- to 3-year-old patients,
and 83% (95% CL, 78% to 88%) and 50% (95%
CL, 47% to 65%) for children aged over 3 years at
the time of conduit replacement. In multivariable
analysis (see Table II) we did not identify age as a
risk factor (p . 0.2). Unlike most other studies, our
analysis excludes early postoperative attrition.
Size of the homograft. Several series suggest that
small conduits constitute a risk factor for early
conduit failure.19, 21, 25 Surprisingly, our follow-up of
conduits still in place 90 days after the original
operation shows no influence of conduit size on
conduit longevity, either when examined as a single
variable or when age at operation (“size for age”) is
taken into account.
Immunologic response. Immunologic response
as a factor in homograft deterioration was suspected
by Clarke and Bishop.27 Schorn and coworkers20
also suspected that immunologic reaction may be a
major factor in homograft deterioration, and they
recommend use of immunosuppression. Baskett and
coworkers26 demonstrated that a short interval from
retrieval to cryopreservation was a risk factor for
homograft failure. The authors speculated that the
short interval may produce “viable” homografts that
could be more antigenic. In our series, ABO or Rh
compatibility between donor and recipient appeared
to confer no advantage.
Conclusion
We have found no factor intrinsic to the conduit
that determines its longevity in the patient. How-
ever, second and subsequent conduits appeared to
fare significantly worse than the first conduit. Con-
duits implanted more recently are electively re-
moved earlier, but patient survival is better than in
our earlier experience.
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Discussion
Dr. F. Mark Lupinetti (Seattle, Wash.). This large and
carefully analyzed experience offers many interesting in-
sights. I was surprised by at least five of the authors’
findings: specifically, redo allografts did worse, more
recent allografts did worse, pulmonary grafts did worse
than aortic grafts, grafts in older patients did worse, and
larger grafts did no better than smaller grafts. That all of
these findings were counterintuitive emphasizes the need
for careful statistical methods and should encourage us to
apply similarly meticulous analyses to our own results.
I have two questions for Mr. Stark regarding the factors
found to be significant by multivariate analysis. First,
would you speculate on at least one possible explanation
for the findings that more recent patients had poor graft
survival? Over the more than two decades of this experi-
ence, presumably the patient population had become
younger and sicker and had more challenging anatomy. Is
it fair to assume that the more complicated nature of the
patients and their operations contributed to the shorter
graft survival in more recent times?
Second, I would like you to comment on the importance
of immunologic factors in the accelerated degeneration of
second and subsequent grafts. Several studies, most nota-
bly that of Mark O’Brien, have shown that recipient
immunosensitization occurs early, affects nearly all allo-
graft recipients, and persists for a long time after implan-
tation. Although I share your bias that technical factors
are the most important determinants of graft success,
don’t your findings also support the hypothesis that im-
mune factors are important as well and that second
allograft failure can be interpreted as a second-set im-
mune response?
Dr. Guillermo O. Kreutzer (Buenos Aires, Argentina).
Our experience with homografts is similar to yours, and I
agree that the greater number of reoperations, the greater
the risk and problems for patients. All currently available
homografts present problems during the long term. Be-
cause of this, in 1983 we started our experience with our
own untreated pericardial valve conduit developed by my
colleague, Dr. Andy Schliecter. Our work was published in
July 1996 in the Annals of Thoracic Surgery. Previous
requirements are mandatory: no previous pericardial ad-
hesions or high pulmonary vascular resistances. Fifty-one
patients were followed up for 1 to 10 years, mean 50
months. In our opinion, it is the only available conduit
whose diameter tends to increase, as happened in 27 of
the 51 patients. Patients with an implanted conduit with a
diameter more than 15 mm do not need to be reoperated
on. Freedom from reoperation in our series is 95.4% at 8
years for patients operated on after January 1986. Conse-
quently, at present it is our conduit of choice until tissue
engineering produces valved conduits with the potential
for growth. Even more, its use is advisable for economic
reasons because reduction of medical costs is mandatory
even in developed countries.
Dr. David B. Ross (Halifax, Nova Scotia, Canada). Mr.
Stark, you postulate in the abstract that flow dynamics
may explain the accelerated rate of failure of second and
subsequent homografts. An alternative explanation, of
course, is that immunologic sensitization may be the
cause, as discussed by Dr. Lupinetti.
In addition to Mark O’Brien’s findings, we have re-
ported an increased risk of failure of homografts on the
right side with very well preserved and thus more anti-
genic grafts.
Corneal grafts are similar to homografts in that they are
implanted without immunosuppression and are thought to
be immunologically privileged. My colleagues in our tis-
sue-typing laboratory report evidence of increased long-
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term survival with HLA-matched corneal grafts. Have you
considered performing this HLA matching prospectively
as we are doing at Halifax?
Dr. Christopher Caldarone (Toronto, Ontario, Canada).
At the Hospital for Sick Children in Toronto we are
concluding an analysis of approximately 905 operations in
which a pulmonary valve or a valved conduit was placed
between the right ventricle and the pulmonary artery. Of
these, there are approximately 400 homografts and ap-
proximately 40% of these were aortic homografts.
By univariate analysis we did not detect a difference
between homograft types. Because we did identify age as
a univariate predictor of valve survival, we performed a
slightly different analysis in that we stratified the group of
patients on the basis of age at operation into four separate
quartiles, the youngest patients in the first quartile, up to
the oldest patients in the fourth quartile. Doing multiva-
riable analysis on each quartile, we found different impor-
tant predictors of valve survival at different ages at
operation.
Specifically, in the first quartile, valve type and size
seemed to be important predictors of valve survival. This
was in an age group ranging from neonates up to 11⁄2
years. In the second and fourth quartiles, valve size was
the only predictor we could detect for conduit survival.
In light of these findings, we would ask whether you
considered an age-based stratified analysis to identify
important factors at different ages at operation. Second,
we are concerned about the use of death as an end point
for conduit failure. If you removed death as an end point
in your analysis, did you find different results?
Dr. Richard A. Hopkins (Providence, R.I.). I have a
comment and a question. I think this is a very important
paper. One always likes to see articles that challenge
currently accepted myths, especially when they support
one’s own beliefs.
Mr. Stark, were the homografts cryopreserved in-house
by you or by others? Did they come from a long distance
or were they from London donors?
Mr. Stark. Dr. Lupinetti, thank you very much for your
comments. We were equally surprised by some of our
findings because we did not expect them. During the last
few years, I personally preferred pulmonary homografts
because in small babies I find the suturing much easier in
pulmonary as opposed to aortic homografts. We were
surprised that pulmonary homografts did not perform as
well as aortic ones. However, in multivariate analysis there
was no difference in longevity between pulmonary and
aortic homografts.
With regard to the performance of redo conduits, there
are possible explanations. When there are adhesions and
calcifications, it may be more difficult to obtain an ideal fit
for the conduit. If we do not obtain ideal flow patterns,
this may contribute to early deterioration of the ho-
mograft.
The explanation for the fact that recent patients had
poor homograft survival is only speculative. As we became
more confident in replacing the homografts, it is possible
that in recent years we have explanted homograft conduits
earlier than previously in the series. In the absence of
clear-cut protocols for conduit replacement, this is cer-
tainly a possibility. When we looked at the survival of
patients, as opposed to survival of the conduits, we found
that patients in the more recent series are surviving better
than in our earlier experience. It may therefore be that
earlier replacement of the conduits is an appropriate
strategy because it is followed by improved rather than
worse patient survival.
With regard to your question about the importance of
immunologic response, I think one has to differentiate
between the use of homografts as aortic valve substitutes
compared with homografts used in conduits in the sub-
pulmonary position. All the data from the literature
suggest that homografts behave differently in these two
positions. Harvesting of homografts in our series was
almost entirely from cadavers; therefore, we cannot claim
that our homografts were “viable.” This, and the fact that
ABO and Rh compatibility did not influence the survival
of our homograft conduits, would suggest that immuno-
logic factors did not play a role.
Dr. Ross, I am aware of the work that was done in
Halifax, in particular your finding that a very short interval
between harvesting and preservation was a risk factor. As
I have already mentioned, we did not think that our
homografts were viable because they were almost always
harvested from cadavers. If the homografts are harvested
at the time of heart transplantation, and the time between
harvest and preservation is very short, it is possible that
immunologic factors play a role. This was also suggested
by the group from Deutsches Herzzentrum in Berlin. I
believe the data from our study cannot add anything to the
question of immunologic response except to state again
that ABO and Rh matching did not play a role.
Dr. Kreutzer, I would include your technique of using
patients’ pericardium in what I called alternative tech-
niques to standard homografts. Your results are outstand-
ing, although the follow-up is only 5 to 7 years. We will
have to wait another 10 to 15 years, but I believe you have
devised a good approach to this difficult problem. The
economic aspect of your operation is also important.
Dr. Caldarone, the way you analyzed your patients in
four separate quartiles is an interesting approach. It is
interesting that the survival of conduits is very similar in
our series and in your Toronto series, but the risk factors
for conduit replacement are different. I have already
discussed this with Dr. Williams. Perhaps we should pool
our results and analyze them as one group. With regard to
your second question, we did not remove death as an end
point in our analysis. Reoperation or death of the patient
with a conduit in place were the end points of our analysis.
We removed only an early death (less than 3 months after
the operation) so as not to confuse patient survival with
conduit survival.
I believe that the Toronto series also supports our idea
that technical aspects may be important. One of the
earlier publications by Razzouk showed considerable dif-
ference if the patient received a homograft conduit com-
pared with pulmonary valve implantation. Irrespective of
what type of pulmonary valve was implanted, the 5-year
survival was 89% whereas the homograft conduit survival
was only 49%. The importance of technical aspects was
also emphasized by data from Boston Children’s Hospital
(Heinemann). This group carefully measured gradients
after the insertion of the conduit. Patients who had a
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mean gradient between the right ventricle and pulmonary
artery of 1.7 mm Hg had much better long-term survival of
conduits than did the group of patients in whom the
gradient was 7 mm Hg. In our series, our operating
reports did not have such detailed information.
Dr. Hopkins, most of our homografts come from the
laboratory that was originally established by Donald Ross
at the National Heart Hospital, which is now located at
the Royal Brompton Hospital. The laboratory preserved
the homografts in antibiotics and nutrient solution, and
cryopreservation was added later as an alternative method
of preservation. The donors came from southern England,
and they were generally cadavers. In addition, when we
could not obtain the desired homograft size from this
laboratory, some homografts were supplied from
Southampton, Sheffield, Liverpool, and Harefield.
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